Connection
Amanda Wieland to Cost-Benefit Analysis
This is a "connection" page, showing publications Amanda Wieland has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.029 |
|
|
|
-
Langness JA, Tabano D, Wieland A, Tise S, Pratt L, Harrington LA, Lin S, Ghuschcyan V, Nair KV, Everson GT. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. Ann Hepatol. 2017 May - Jun; 16(3):366-374.
Score: 0.029